An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy

AstraZeneca

Status: Terminated

Conditions: Non-small Cell Lung Cancer; Lung Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT00721981

NIS-ODE-DUM-2008/1

Details and patient eligibility

About

The main purpose of this study is the identification, description, and segmentation of non-small cell lung cancer (NSCLC) patients based on their value appraisal of treatment outcomes and all intermediate states of health, to obtain patient preferences in direct correlation with clinical data from patients suffering from NSCLC (stage IIIB / IV) who are in transition from 1st to 2nd line treatment, and to gain utility scores by health state derived from patients' perceived value and taken from their perspective.

Enrollment: 120 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients suffering from non-small cell lung cancer (NSCLC) with clinical stage IIIB and IV tumours
• Patients with one chemotherapy regimen (first line treatment) (adjuvant chemotherapy following surgery is also regarded as first line treatment)
• Patients who are in transition from first to second line treatment
• Patients who signed an informed consent

Exclusion criteria

• Chemotherapy naïve patients
• Patients ever enrolled in clinical studies treating non-small cell lung cancer (NSCLC) with chemotherapy (during 1st and 2nd line chemotherapy)
• Patients who ever had chemotherapy for an indication other than NSCLC

Trial design

120 participants in 1 patient group

1

Description:

Regular treatment for non-small cell lung cancer (NSCLC)